MDT’s stock remains above its 200‑day moving average with a 1.8% week‑over‑week gain, and the recent earnings beat plus a limited recall has reinforced its top‑line visibility. The balance sheet remains strong with $6 B of cash and a 2.5% dividend yield, supporting a bullish outlook.

Investors are shifting focus from the turbulence in Intuitive and Abbott to more stable med‑tech names, and MDT is being viewed as a defensive play amid sector volatility. This sentiment shift keeps buying pressure on MDT, maintaining a bullish tone.

While the recall risk is now largely contained, regulatory scrutiny and competition could pose medium‑term challenges for MDT. Nonetheless, its broad product mix and aging‑population tailwinds underpin a bullish long‑term view.

Technical indicators show a bullish MACD crossover, RSI at 58, and daily volume 20% above its 30‑day average, confirming upward momentum. The price is holding the $115 support level, suggesting further upside.